62098-74-2

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
(3,5-DIMETHOXY-BENZOYLAMINO)-ACETIC ACID is utilized as a key building block for the synthesis of biologically active molecules. Its unique structure allows for the development of new pharmaceutical agents with potential applications in treating various diseases and conditions.
Used as an Enzyme Inhibitor:
In the field of medicinal chemistry, (3,5-DIMETHOXY-BENZOYLAMINO)-ACETIC ACID is studied for its potential as an enzyme inhibitor. By inhibiting certain enzymes, it may contribute to the management or treatment of specific medical conditions by disrupting the biochemical pathways associated with disease progression.
Used as a Therapeutic Agent:
(3,5-DIMETHOXY-BENZOYLAMINO)-ACETIC ACID is also considered for its potential as a therapeutic agent. Its capacity to interact with biological targets makes it a candidate for the treatment of various medical conditions, offering new possibilities for patient care and disease management.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, (3,5-DIMETHOXY-BENZOYLAMINO)-ACETIC ACID is employed for its potential to contribute to the discovery and development of new drugs. Its versatility and chemical properties make it a promising candidate for further research and application in creating novel pharmaceuticals.

Upstream product

• 1132-21-4 3,5-dimethoxybenzoic acid 
• 17213-57-9 3,5-dimethoxybenzoyl chloride 
• 56-40-6 glycine 

Relevant academic research and scientific papers

Design, Synthesis, and Evaluation of the Anticancer Properties of a Novel Series of Imidazolone Fused Pyrazolo[1,5-a]pyrimidine Derivatives

A novel series of imidazolone fused pyrazolo[1,5-a]pyrimidine derivatives has been designed and synthesized using a convergent approach, and the structures of these compounds were confirmed by 1H NMR, 13C NMR, ESI-MS, and IR analyses. These new compounds were tested for their in vitro antiproliferative activity using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Out of the 20 derivatives prepared in the current study, compounds 8h, 8n, and 8r exhibited good anticancer activities tested against HeLa cells and HepG2 cells. However, the in vitro anticancer activity of compound 8r against HeLa, HepG2, and MCF-7 cell lines is superior to the marketed drugs Paclitaxel and SAHA.

Synthesis and Quantitative Structure-activity Relationships Study for Arylpropenamide Derivatives as Inhibitors of Hepatitis B Virus Replication

A series of new arylpropenamide derivatives containing different aryl groups were synthesized, characterized, and evaluated for their anti-hepatitis B virus (HBV) activities. A new high accuracy QSAR model of arylpropenamide was constructed based on a more completely activities data and calculation parameter. The 2D-QSAR equations, by using DFT and multiple linear regression analysis methods, revealed that higher value of thermal energy (TE) and lower entropy (S?) increase the anti-HBV activities of the arylpropenamide molecules. Predictive 3D-QSAR models were established by SYBYL multifit molecular alignment rule. The optimum models were all statistically significant with cross-validated and conventional coefficients, indicating that they were reliable enough for activity prediction.